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Worldwide prevalence of dementia is estimated to rise from the current 50 million people affected to 
152 million by 2050, costing healthcare systems ~2% of the global GDP to diagnose, treat and care 
for patients [1]. Although there are over 130 different types of dementia, Alzheimer’s disease (AD) 
accounts for 60-70% of all cases. Methods for early diagnosis of AD could significantly impact disease 
detection, progression monitoring and therapeutics. This grand challenge requires ultra-sensitive and 
specific sensors to detect concentration level changes in patients significantly earlier than current 
diagnostic techniques employing MRI, CT, PET scans, blood tests and memory tests, often taking 
around 2 years to complete. We have therefore developed novel graphene/hBN transducers for the 
ultra-sensitive detection of AD protein biomarkers, such as Clusterin a molecular chaperone 
associated with AD, using electrical Quantum Transport Admittance Spectroscopy (e-QTAS). The 
graphene/hBN [2] transducers were fabricated on Si/SiO2 substrate using photolithography with 
evaporated chromium and sputtered gold contacts. The transducer channels were functionalized with 
linker molecules, 1-Pyrenebutyric acid N-hydroxysuccinimide (Pyr-NHS) ester, to immobile anti-
Clusterin antibody (Ab) [3]. Binding reaction of the antibody with varying concentration levels of 
Clusterin antigen demonstrated the limit of detection of the transducers to be better than 10 fg/mL 
using four-probe direct current-voltage (DC-IV) and e-QTAS [4,5]. The developed transducers are 
generic, selective, fast, low-cost and could find applications in a broad range of point-of-care medical 
diagnostics in addition to neurodegenerative diseases (Alzheimer’s, Parkinson’s, etc.), such as cancer 
and cardiovascular disorders. We acknowledge funding from the UK’s EPSRC, EP/M006301/1 and 
University of Plymouth, GD105227.           
 
 














Fig. 1. Graphene/hBN device functionalisation (A: Graphene/hBN, B: Pyr-NHS, C: Ab, D: Bovine 
Serum Albumin E: Clusterin) with inset showing fabricated transducers for the detection of Clusterin, 
key a biomarker of AD.  
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